Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: November 11, 2022
Expiration Date: November 11, 2023

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Several JAK inhibitors are now approved for the treatment of myelofibrosis (MF). Ruxolitinib is considered the standard of care for managing symptomatic MF and, as such, is most often used in the frontline treatment setting. Peer-reviewed literature reflects the pervasive use of ruxolitinib in the frontline MF setting, and the overwhelming majority of data available for study and review in these patients involves ruxolitinib. This data is clear: the majority of patients will either fail to respond or lose response to ruxolitinib over time. Treatment resistance and loss of response can be difficult to identify and define. In this activity, two experts describe risk factors for disease progression, review methods of assessing for and identifying resistance, and how to manage treatment failure.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with myelofibrosis.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Recall risk factors for disease progression and resistance/loss of response with ruxolitinib therapy
  • Review methods of assessing for and identifying primary resistance, loss of an initial response, drug intolerance, or progressive disease during JAK inhibitor treatment
  • Identify and manage ruxolitinib treatment resistance, failure and/or loss of response

Agenda

Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response – Prithviraj Bose, MD and John Mascarenhas, MD

Instructions for Participation and Credit

This activity is eligible for credit through November 11, 2023. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and NCPD may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Prithviraj Bose, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Prithviraj Bose obtained his medical degree from the Calcutta Medical College at the University of Calcutta in Kolkata, India. He completed an internship in internal medicine at a University of Washington affiliate in Spokane, and residency at the Henry Ford Hospital in Detroit, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City. Dr. Bose is currently an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center (MDACC), Houston, Texas.

Dr. Bose has published more than 250 peer-reviewed journal articles, book chapters, and scientific meeting abstracts. His work has appeared in The New England Journal of Medicine, Cancer Cell, Blood, Leukemia, Clinical Infectious Diseases and Williams’ Hematology. Additionally, he has served as a peer-reviewer for multiple hematology and oncology journals, including The New England Journal of Medicine, The Lancet Oncology, JAMA Oncology, Blood, and many others.

Dr. Bose’s major clinical and research focus is on myeloproliferative neoplasms (MPNs). He has presented his research at major international conferences such as the annual ASH and EHA meetings, authored numerous articles on MPN topics in peer-reviewed journals and books, and regularly speaks on MPN at national and regional meetings. He is also heavily involved in clinical trial design for patients with MPNs, and in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis, polycythemia vera and systemic mastocytosis at MDACC. Dr. Bose represents MD Anderson on the MPN and systemic mastocytosis panels of the National Comprehensive Cancer Network.

John Mascarenhas, MD
Associate Professor of Medicine
Tisch Cancer Institute, Division of Hematology/Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. He is the Director of the Adult Leukemia Program and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs), he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr. Mascarenhas is also the principal investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or study chair of multiple investigator-initiated and industry-sponsored early- and late-phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary leukemia.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME).

MediCom Worldwide, Inc. The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing
The University of Texas MD Anderson Cancer Center is accredited with distinction as a provider of Nursing Continuing Professional Development by The American Nurses Credentialing Center’s Commission on Accreditation.

The University of Texas MD Anderson Cancer Center designates this live activity and will award 0.50 Nursing Continuing Professional Development (NCPD) contact hours.
ACPE CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-018-H01-P. Knowledge-based
CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

As an organization accredited by the Accreditation Council for Pharmacy Education (ACPE), MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company.

Faculty Disclosures

Dr. Prithviraj Bose has relevant financial relationships related to advisory activities from AbbVie Inc., Blueprint Medicines, Bristol Myers Squibb Company, Cogent Biosciences, Inc., Constellation Pharmaceuticals, CTI BioPharma Corp., Karyopharm Therapeutics, MorphoSys AG, Novartis AG, PharmaEssentia Corporation, and Sierra Oncology, Inc. He is on the speakers’ bureau for Bristol Myers Squibb, CTI BioPharma, Incyte Corporation, and Sierra Oncology.

Dr. John Mascarenhas has relevant financial relationships related to consulting from AbbVie Inc., Bristol Myers Squibb Company, Celgene Corporation ‒ A Bristol Myers Squibb Company, Constellation Pharmaceuticals, CTI BioPharma Corp., F. Hoffmann-La Roche Ltd, Incyte Corporation, Galecto Biotech, GlaxoSmithKline plc, Geron, Imago BioSciences, Kartos Therapeutics, Inc., Novartis AG, PharmaEssentia Corporation, and Sierra Oncology, Inc. He serves on the Data and Safety Monitoring Board (DSMB) for Karyopharm Therapeutics.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee Disclosures

The following planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
MediCom Worldwide, Inc.: Joan Meyer, RN, MHA, Executive Director, and Andrea Mathis, Project Manager
The University of Texas MD Anderson Cancer Center: Tamara Greiner, MA, Associate Director, and Danya Garner, MSN, Associate Director, CPE

Peer Reviewer Disclosure

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding the content of this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242, x 130 or email us at [email protected]

Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb, CTI BioPharma Corp. and Sierra Oncology.

©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.